Keeping Track: The Breakthrough Designations Of Summer Eschew Phase I
Executive Summary
The latest breakthrough therapy designation announcements from the Pink Sheet’s US FDA Performance Tracker
You may also be interested in...
Keeping Track: Chiesi Breathes Easier With Bronchitol Approval; Submissions Aplenty From GSK, Pfizer, AZ, AbbVie
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
ASCO 2020: Pevonedistat Shows Promise In Higher-Risk MDS
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.
MyoKardia Readies First-Ever Hypertrophic Cardiomyopathy Drug For US Filing
The Phase III EXPLORER-HCM trial evaluating mavacamten in obstructive hypertrophic cardiomyopathy (oHCM) succeeded on all primary and secondary endpoints.